Sinobiomed Inc. (SOBM.OB) is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Sinobiomed employs a patented, low-cost, high-yield production process to enhance bioactivity and guarantee the highest levels of purity.
Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials, and three in R&D. The company’s products respond to a wide range of diseases and conditions, including hepatitis B&C, surgical bleeding, diabetic ulcers and burns, malaria, cancer, rheumatoid arthritis, acute liver disease, stroke, blood clots and thrombosis, acute pancreatitis, and blood cell regeneration.
Sinobiomed has several competitive advantages in addition to the company’s patented recombinant protein manufacturing process. One advantage is the company’s strong strategic alliances with leading Chinese research hospitals and institutes for collaborative development of patentable techniques and treatments. Another advantage is the company’s distribution network.
Sinobiomed has also established a nationwide sales and marketing network along with international marketing support programs. The company’s sales efforts were enhanced by its purchase in September, 2007 of a 90% interest in the Suzhou Boai Medical Development Company. Suzhou is an established Chinese pharmaceutical distribution company. Sinobiomed expects the acquisition will expand its market reach and accelerate sales.
Let us hear your thoughts below: